Did we have a clearing event with the confirmation of RFK JR or is that copium? The initial indication is that there has been a little relief rally and if we can keep as close to the old status quo as possible (not too many massive changes) and rates can come down then the sector […]
February 11th Biotech Update
Still not looking great for the sector. While there is not a ton of positive news to move the sector forward, rates are starting to tick higher. Perhaps this is only a momentary move, and we will reverse lower on rates but if rates start a more consistent move higher, then there is no shot […]
February 10th Biotech Update
Well, we have not been able to breakout and now are back at the lower end of the potential range. We really need to hold these levels as we do not want to be talking about a potential breakdown. We are not there yet but we are getting closer to that point. I am not […]
Eupraxia – The Precision Delivery Platform
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company headquartered in Victoria, British Columbia, Canada. The company focuses on developing locally delivered, extended-release alternatives to currently approved drugs. Their goal is to provide targeted, long-lasting activity with fewer side effects. Eupraxia’s lead product candidate, EP-104GI for treating eosinophilic esophagitis (EoE). EoE is a chronic, immune-mediated […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
